A five-year-old boy with a rare form of dementia requires nearly £3 million for a newly approved gene therapy treatment in the US. His mother, Tammy McDaid, has raised over £160,000 but faces uncertainty regarding funding options for families in the UK and elsewhere. Health officials in Wales are exploring potential access pathways for the treatment.
The urgency is heightened as the condition can progress rapidly after age five, and Tammy is concerned about her son's cognitive decline. The pharmaceutical company Ultragenyx is working on a global regulatory strategy to make the treatment available internationally.
Tammy McDaid's urgent fundraising for her son's gene therapy highlights the need for clearer funding pathways in the UK. Watch for developments from Welsh health officials and Ultragenyx's global strategy, as families worldwide seek access to this critical treatment.